Utility Of the multivariate approach in predicting β-Thalassemia intermedia or β-Thalassemia major types in iranian patients

Hemoglobin

Volumn 37, Issue 5, 2013, Pages 413-422

  Banan, Mehdi ^a   Bayat, Hadi ^a   Namdar Aligoodarzi, Pegah ^a   Azarkeivan, Azita ^b   Kamali, Koorosh ^c   Daneshmand, Parvaneh ^a   Zaker Kandjani, Behzad ^a   Najmabadi, Hossein ^a  

^a UNIVERSITY OF SOCIAL WELFARE AND REHABILITATION SCIENCES   (Iran)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Thalassemia ( thal); Thalassemia intermedia ( TI); Thalassemia major ( TM); BCL11A; Phenotype genotype; XmnI Polymorphism

Indexed keywords

HEMOGLOBIN BETA CHAIN;

ADULT; ALPHA THALASSEMIA; ARTICLE; BLOOD TRANSFUSION; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC MARKER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR;

ADULT; BETA-GLOBINS; BETA-THALASSEMIA; BINDING SITES; CARRIER PROTEINS; COHORT STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; DNA, INTERGENIC; FEMALE; GENE FREQUENCY; GENOTYPE; GTP-BINDING PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IRAN; MALE; MULTIVARIATE ANALYSIS; MUTATION; NUCLEAR PROTEINS; PEPTIDE ELONGATION FACTORS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYB; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84873991875     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2013.805418     Document Type: Article

References (28)

1. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5):512-523
2. Aessopos A, Angelucci E, Antoniou M, et al. Blood transfusion therapy in β-thalassemia major. In: Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A, Eds. Guidelines for the Clinical Managment of Thalassemia, 2nd ed. Nicosia: Thalassemia International Federation. 2008:20-32
3. Olivieri NF, Weatherall DJ. Clinical aspects of β thalassemia and related disorders. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed. Cambridge: Cambridge University Press. 2009:357-416
4. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis. 2006; 37(1):12-20
5. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias. Nat Rev Genet. 2001;2(4):245-255
6. Thein SL, Wood WG. The molecular basis of β thalassemia, δβ thalassemia, and hereditary persistence of fetal hemoglobin. In: Steinberg MH, Forget BG, Higgs DR, Weatherall DJ, Eds. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 2nd ed. Cambridge: Cambridge University Press. 2009:323-356
7. Thein SL. Genetic modifiers of β-thalassemia. Haematologica. 2005;90(5):649-660
8. Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia. Proc Natl Acad Sci USA. 2008;105(5):1620-1625
9. Lettre G, Sankaran VG, Bezerra MAC, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA. 2008;105(33):11869-11874
10. Galarneau G, Palmer CD, Sankaran VG, Orkin SH, Hirschhorn JN, Lettre G. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet. 2010; 42(12):1049-1051
11. Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with β-hemoglobinopathies. Blood Cells Mol Dis. 2008;41(3):255-258
12. Nguyen TK, Joly P, Bardel C, Moulsma M, Bonello-Palot N, Francina A. The XmnI Gγ polymorphism influences Hemoglobin F synthesis contrary to BCL11A and HBS1L-MYB SNPs in a cohort of 57 β-thalassemia intermedia patients. Blood Cells Mol Dis. 2010;45(2):124-127
13. Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839-1842
14. Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093-1097
15. Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood. 2006;108(3):1077-1083
16. Sankaran VG, Xu J, Byron R, et al. A functional element necessary for fetal hemoglobin silencing. N Engl J Med. 2011;365(9):807-814
17. Galanello R, Sanna S, Perseu L, et al. Amelioration of Sardinian β0 thalassemia by genetic modifiers. Blood. 2009;114(18):3935-3937
18. Badens C, Joly P, Agouti I, et al. Variants in genetic modifiers of β-thalassemia can help to predict the major or intermedia type of the disease. Haematologica. 2011;96(11):1712-1714
19. Danjou F, Anni F, Galanello R. β-Thalassemia: From genotype to phenotype. Haematologica. 2011; 96(11):1573-1575
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215
21. Banan M, Bayat H, Azarkeivan A, et al. The XmnI and BCL11A single nucleotide polymorphisms may help predict hydroxyurea response in Iranian β-thalassemia patients. Hemoglobin. 2012;36(4):371- 380
22. Arab A, Karimipoor M, Rajabi A, Hamid M, Arjmandi S, Zeinali S. Molecular characterization of β- Thalassemia intermedia: A report from Iran. Mol Biol Rep. 2010;38(7):4321-4326
23. Karimi M, Yarmohammadi H, Farjadian S, et al. β-Thalassemia intermedia from southern Iran: IVS-II-1 (G!A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002;26(2):147-154
24. Cao A, Moi P, Galanello R. Recent advances in β-thalassemias. Pediatr Rep. 2011;3(2):e17
25. Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: Genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood. 2010 115(9):1815-1822
26. Borg J, Patrinos GP, Felice AE, Philipsen S. Erythroid phenotypes associated with KLF1 mutations. Haematologica. 2011;96(5):635-638
27. Gallienne AE, Dreau HMP, Schuh A, Old JM, Henderson S. Ten novel mutations in the erythroid transcription factor KLF1 gene associated with increased fetal hemoglobin levels in adults. Haematologica. 2012;97(3):340-343
28. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: New insights emerging from genomics and clinical implications. Hum Mol Genet. 2009;18(R2):R216-223